Tolterodine ER + Oxybutynin ER
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Memory
Conditions
Memory, Cognition
Trial Timeline
Dec 1, 2006 → Jun 1, 2007
NCT ID
NCT00411437About Tolterodine ER + Oxybutynin ER
Tolterodine ER + Oxybutynin ER is a approved stage product being developed by Pfizer for Memory. The current trial status is completed. This product is registered under clinical trial identifier NCT00411437. Target conditions include Memory, Cognition.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00411437 | Approved | Completed |
Competing Products
8 competing products in Memory
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 85 |
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 33 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 51 |
| Levetiracetam, Keppra | UCB | Approved | 82 |
| Piracetam | UCB | Pre-clinical | 20 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 82 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 47 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 15 |